Invest in Glenmark Pharma: Prakash Diwan

Prakash Diwan of Asit C Mehta feels that one should invest in Glenmark Pharma.

Mehta told CNBC-Awaaz, "Investors should invest in Glenmark Pharma. The stock is looking good in pharma space. It is trading well with good valuation. It can give attractive return in future."
The company's trailing 12-month (TTM) EPS was at Rs 8.28 per share. (Jun 2011). The stock's price-to-earnings (P/E) ratio was 38.49. The latest book value of the company is Rs 73.22 per share. At current value, the price-to-book value of the company was 4.35. The dividend yield of the company was 0.13%.